Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALVO declined for three days, in 233 of 294 cases, the price declined further within the following month. The odds of a continued downward trend are 79%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALVO as a result. In 71 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for ALVO turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 33 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
ALVO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALVO crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for ALVO entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALVO's RSI Oscillator exited the oversold zone, 25 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALVO advanced for three days, in 199 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
ALVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.057) is normal, around the industry mean (6.379). P/E Ratio (-7.839) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where XERS advanced for three days, in 222 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on XERS as a result. In 71 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for XERS just turned positive on November 05, 2026. Looking at past instances where XERS's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 191 of 232 cases where XERS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
XERS broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XERS's P/B Ratio (-284.700) is very low in comparison to the industry average of (6.379). XERS has a moderately low P/E Ratio (-152.000) as compared to the industry average of (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.196) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ALVO | XERS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 47 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 5 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 60 | 34 | |
P/E GROWTH RATING 1..100 | 98 | 99 | |
SEASONALITY SCORE 1..100 | 85 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XERS's Valuation (1) in the Pharmaceuticals Major industry is in the same range as ALVO (7) in the null industry. This means that XERS’s stock grew similarly to ALVO’s over the last 12 months.
XERS's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is significantly better than the same rating for ALVO (100) in the null industry. This means that XERS’s stock grew significantly faster than ALVO’s over the last 12 months.
XERS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as ALVO (100) in the null industry. This means that XERS’s stock grew similarly to ALVO’s over the last 12 months.
XERS's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as ALVO (60) in the null industry. This means that XERS’s stock grew similarly to ALVO’s over the last 12 months.
ALVO's P/E Growth Rating (98) in the null industry is in the same range as XERS (99) in the Pharmaceuticals Major industry. This means that ALVO’s stock grew similarly to XERS’s over the last 12 months.
| ALVO | XERS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | 2 days ago 80% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 72% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 69% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 86% |
| Advances ODDS (%) | 7 days ago 74% | 2 days ago 86% |
| Declines ODDS (%) | 5 days ago 79% | 16 days ago 77% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 73% |
| Aroon ODDS (%) | 2 days ago 77% | 2 days ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALVO’s FA Score shows that 1 FA rating(s) are green while XERS’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALVO’s TA Score shows that 4 TA indicator(s) are bullish while XERS’s TA Score has 4 bullish TA indicator(s).
ALVO (@Pharmaceuticals: Generic) experienced а -6.08% price change this week, while XERS (@Pharmaceuticals: Generic) price change was +5.30% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.48%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -7.77%.
ALVO is expected to report earnings on Mar 10, 2027.
XERS is expected to report earnings on Mar 10, 2027.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
A.I.dvisor tells us that ALVO and EBS have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALVO and EBS's prices will move in lockstep.
| Ticker / NAME | Correlation To ALVO | 1D Price Change % | ||
|---|---|---|---|---|
| ALVO | 100% | +5.13% | ||
| EBS - ALVO | 30% Poorly correlated | +0.35% | ||
| CRON - ALVO | 24% Poorly correlated | -3.25% | ||
| XERS - ALVO | 23% Poorly correlated | +0.24% | ||
| PAHC - ALVO | 22% Poorly correlated | -2.64% | ||
| SIGA - ALVO | 22% Poorly correlated | +4.01% | ||
More | ||||
A.I.dvisor indicates that over the last year, XERS has been loosely correlated with MIRM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then MIRM could also see price increases.
| Ticker / NAME | Correlation To XERS | 1D Price Change % | ||
|---|---|---|---|---|
| XERS | 100% | +0.24% | ||
| MIRM - XERS | 45% Loosely correlated | -2.56% | ||
| KROS - XERS | 38% Loosely correlated | -2.62% | ||
| AXON - XERS | 37% Loosely correlated | -2.85% | ||
| REPL - XERS | 36% Loosely correlated | -2.19% | ||
| COLL - XERS | 36% Loosely correlated | +0.43% | ||
More | ||||